Acrux Ltd (ASX: ACR) Share Price and News
Price
$0.023
Movement
0.00 (0.0)
as at 23 May - Closed (20 mins delayed)
52 Week Range
$0.022 - $0.088
1 Year Return
-64.62%
Acrux Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$9.37 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
407.32 million
Earnings per share
-0.020
Dividend per share
N/A
Year To Date Return
-30.30%
Earnings Yield
N/A
Franking
-
Share Price
$0.023
Day Change
0.00 (0.0)
52 Week Range
$0.022 - $0.088
Yesterday's Close
$0.023
Today's Open
$0.024
Days Range
$0.023 - $0.024
Volume
312,969
Avg. Volume (1 month)
182,529
Turnover
$7,335
as at 23 May - Closed
Acrux Ltd (ASX: ACR)
Latest News
Investing
3 solid stocks that Mr Market hates today
Investing
5 health care stocks to supercharge your portfolio
Investing
2 pharmaceutical stocks growing sales in the giant US drug market – should you buy?
Investing
Could these 4 bruised biotech stocks be about to recover?
Investing
Your instant 6-share biotech portfolio
Investing
Acrux Limited tumbles 10.3%
ACR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 23rd May 2025 2025-05-23T09:11:14 | Appendix 3Y Brumley | YesNo | 9:11am | 2 | 217k |
| 23rd May 2025 2025-05-23T09:10:24 | Application for quotation of securities - ACR | YesNo | 9:10am | 5 | 15k |
| 23rd May 2025 2025-05-23T09:05:19 | Notification of cessation of securities - ACR | YesNo | 9:05am | 4 | 13k |
| 9th May 2025 2025-05-09T08:33:11 | Dapsone 7.5%, Gel launched in the United States | YesNo | 8:33am | 2 | 149k |
| 7th May 2025 2025-05-07T09:12:28 | Acrux CEO and Managing Director appointment | YesNo | 9:12am | 3 | 152k |
| 30th Apr 2025 2025-04-30T10:03:33 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 10:03am | 7 | 345k |
| 9th Apr 2025 2025-04-09T12:18:13 | Details of Share Registry address | YesNo | 12:18pm | 1 | 118k |
| 4th Apr 2025 2025-04-04T09:11:14 | Appendix 3Y Dobinson | YesNo | 9:11am | 2 | 174k |
| 4th Apr 2025 2025-04-04T09:08:19 | Application for quotation of securities - ACR | YesNo | 9:08am | 6 | 16k |
| 3rd Apr 2025 2025-04-03T09:32:43 | Acrux receives $1.73m advance on FY25 R&D Tax Incentive | YesNo | 9:32am | 1 | 120k |
About Acrux Ltd
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and othercountries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone TopicalSolution, and among others.
ACR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 May 2025 | $0.02 | $0.00 | 0.00% | 312,969 | $0.02 | $0.02 | $0.02 |
| 22 May 2025 | $0.02 | $0.00 | 0.00% | 726,648 | $0.02 | $0.02 | $0.02 |
| 20 May 2025 | $0.02 | $0.00 | 0.00% | 144,935 | $0.02 | $0.02 | $0.02 |
| 16 May 2025 | $0.02 | $0.00 | 0.00% | 469,927 | $0.03 | $0.03 | $0.02 |
| 15 May 2025 | $0.03 | $0.00 | 0.00% | 211,540 | $0.03 | $0.03 | $0.03 |
| 14 May 2025 | $0.03 | $0.00 | 0.00% | 393,406 | $0.03 | $0.03 | $0.03 |
| 13 May 2025 | $0.03 | $0.00 | 0.00% | 561,632 | $0.03 | $0.03 | $0.03 |
| 12 May 2025 | $0.03 | $0.00 | 0.00% | 132,241 | $0.03 | $0.03 | $0.03 |
| 09 May 2025 | $0.03 | $0.00 | 0.00% | 576,244 | $0.03 | $0.03 | $0.02 |
| 08 May 2025 | $0.02 | $0.00 | 0.00% | 3,000 | $0.02 | $0.02 | $0.02 |
| 07 May 2025 | $0.02 | $0.00 | 0.00% | 148,700 | $0.02 | $0.02 | $0.02 |
| 06 May 2025 | $0.02 | $0.00 | 0.00% | 62,393 | $0.02 | $0.02 | $0.02 |
| 05 May 2025 | $0.02 | $0.00 | 0.00% | 20,119 | $0.02 | $0.02 | $0.02 |
| 02 May 2025 | $0.02 | $0.00 | 0.00% | 60,000 | $0.02 | $0.02 | $0.02 |
| 01 May 2025 | $0.02 | $0.00 | 0.00% | 171,564 | $0.02 | $0.02 | $0.02 |
| 29 Apr 2025 | $0.02 | $0.00 | 0.00% | 11,636 | $0.02 | $0.02 | $0.02 |
| 28 Apr 2025 | $0.02 | $0.00 | 0.00% | 84,748 | $0.02 | $0.02 | $0.02 |
| 24 Apr 2025 | $0.02 | $0.00 | 0.00% | 43,716 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Apr 2025 | Ross Dobinson | Issued | 571,428 | $12,571 |
Placement. As per announcement on 04-04-2025
|
| 04 Mar 2025 | Ross Dobinson | Issued | 571,428 | $20,000 |
Placement.
|
| 19 Feb 2025 | Geoffrey Brooke | Issued | 285,714 | $8,857 |
Placement.
|
| 19 Feb 2025 | Timothy Oldham | Issued | 285,714 | $8,857 |
Placement.
|
| 19 Feb 2025 | Michael Kotsanis | Issued | 857,142 | $26,571 |
Placement. As per announcement on 19-02-2025
|
| 19 Feb 2025 | Donald Brumley | Issued | 2,285,714 | $70,857 |
Placement.
|
| 13 Feb 2025 | Donald Brumley | Issued | 2,285,714 | $80,000 |
Placement.
|
| 13 Feb 2025 | Michael Kotsanis | Issued | 857,142 | $30,000 |
Placement.
|
| 13 Feb 2025 | Geoffrey Brooke | Issued | 285,714 | $10,000 |
Placement.
|
| 13 Feb 2025 | Timothy Oldham | Issued | 285,714 | $10,000 |
Placement.
|
| 12 Dec 2024 | Donald Brumley | Issued | 896,668 | $28,693 |
Issue of securities. 1,693,878 Rights
|
| 12 Dec 2024 | Donald Brumley | Exercise | 797,210 | $25,510 |
Conversion of securities.
|
| 12 Dec 2024 | Donald Brumley | Issued | 797,210 | $25,510 |
Conversion of securities.
|
| 12 Dec 2024 | Timothy Oldham | Issued | 1,062,946 | $34,014 |
Conversion of securities.
|
| 12 Dec 2024 | Timothy Oldham | Exercise | 1,062,946 | $34,014 |
Conversion of securities. 896,668 unlisted rights
|
| 12 Dec 2024 | Timothy Oldham | Issued | 896,668 | $28,693 |
Issue of securities. 1,959,614 Rights
|
| 12 Dec 2024 | Ross Dobinson | Issued | 1,411,994 | $45,183 |
Issue of securities. 2,668,548 Rights
|
| 12 Dec 2024 | Geoffrey Brooke | Issued | 896,668 | $28,693 |
Issue of securities. 1,959,614 rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Ross Dobinson | Non-Executive ChairmanNon-Executive Director | Jul 2012 |
Mr Dobinson has a background in investment banking and stockbroking. He was a founding Director of Starpharma Holdings Limited (ASX: SPL) and was formerly a Director of Reliance Worldwide Corporation (ASX: RWC), Executive Director of Hexima Limited (ASX: HXL), Chairman of TPI Enterprises Limited (now Palla Pharma Ltd. ASX: PAL), Director of Roc Oil Company Limited (ASX: ROC) and a Director of Racing Victoria Limited.
|
| Dr Geoffrey E.D Brooke | Non-Executive Director | Jun 2016 |
Dr Brooke has more than 30 years of venture capital experience. In 2014, he sold his involvement in GBS and now concentrates on privately investing in a small number of companies. He is a member of Risk and Human Capital Committee.
|
| Dr Timothy Oldham | Non-Executive Director | Oct 2013 |
Dr Oldham has 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is the Chair of the Human Capital Committee and also a member of Risk Committee.
|
| Mr Michael John Kotsanis | Chief Executive OfficerManaging Director | Nov 2014 |
Mr Kotsanis has more than 30 years of experience in the global pharmaceutical industry including significant senior leadership experience. Prior to Faulding, Michael held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11-year period.
|
| Mr Donald Charles Brumley | Non-Executive Director | Jun 2021 |
Mr Brumley has 30 years of experience as a senior partner of Ernst & Young, Oceania. He has experience in IPOs, transactions and audit and has advised and worked with Boards of organisations ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. He is the Chair of the Risk Committee and also a member of Human Capital Committee.
|
| Ms Joanna Johnson | Chief Financial OfficerCompany Secretary | Jun 2021 |
-
|
| Joanna Johnson | Chief Financial OfficerCompany Secretary |
-
|
|
| Felicia Colagrande | Product Development and Technical Affairs Director |
-
|
|
| Mark Hyman | Project and Technical Development Director |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Phillip Asset Management Limited | 31,847,134 | 10.95% |
| Hishenk Pty Ltd | 11,000,000 | 3.78% |
| Mr Ross Dobinson | 5,249,245 | 1.81% |
| Dr Thomas Vui Chung Chai | 4,951,985 | 1.70% |
| Willoughby Capital Pty Ltd | 4,500,000 | 1.55% |
| Citicorp Nominees Pty Limited | 4,149,492 | 1.43% |
| Mr Christopher Murray Abbott | 4,000,000 | 1.38% |
| Ashwood River Pty Ltd | 3,800,000 | 1.31% |
| The Poole Family Superannuation Fund Pty Ltd | 3,700,000 | 1.27% |
| Mr Donald Charles Brumley | 3,396,108 | 1.17% |
| Netwealth Investments Limited | 3,284,269 | 1.13% |
| Mr Alan Jebb & Mrs Sandra Jebb | 3,100,000 | 1.07% |
| MNA Family Holdings Pty Ltd | 2,800,000 | 0.96% |
| TSO Pty Ltd | 2,625,734 | 0.90% |
| Mr Bikash Kaji Baniya | 2,339,711 | 0.80% |
| HSBC Custody Nominees (Australia) Limited | 2,100,674 | 0.72% |
| Pacific Custodians Pty Limited | 2,048,427 | 0.70% |
| Mr Ian Victor Lancini & Mrs Debra Ann Lancini | 2,045,000 | 0.70% |
| Mr Zirong Pu | 2,023,000 | 0.70% |
| Adam Jamal | 1,905,719 | 0.66% |
| Mr Michael John Kotsanis | 1,511,083 | 0.52% |
| Mr Allen James Kirby | 1,500,000 | 0.52% |
| Mr David Andrew Slobom & Mrs Linda Jane Slobom | 1,409,596 | 0.48% |
| NewEconomy Com Au Nominees Pty Limited | 1,327,870 | 0.46% |
| Mrs Nola Kendall Fletcher | 1,300,000 | 0.45% |